{
    "symbol": "TKNO",
    "quarter": 4,
    "year": 2022,
    "date": "2023-03-15 20:04:06",
    "content": " Revenue for the fourth quarter of 2022 was $7.9 million, an 18% decline from $9.6 million in the fourth quarter of 2021 and $41.4 million for the full year 2022, a 17% increase from $35.4 million for the year 2021, excluding Sample Transport. Lab Essentials revenue was $7.0 million in the fourth quarter, a 3% increase from $6.7 million in the fourth quarter of 2021. For the full year, Lab Essentials revenue was $31.8 million, a 17% increase from $27.2 million for the full year 2021. Clinical Solutions revenue was $0.8 million in the fourth quarter, a 68% decrease from $2.4 million in the fourth quarter of 2021. For the full year, Clinical Solutions revenue was $8.4 million, a 24% increase from $6.8 million for the full year 2021. Gross margin was 26.7% of revenue in the fourth quarter 2022, which is down from 49.2% of revenue in the fourth quarter of 2021 and 42.2% for the full year 2022, which is down from 47.8% for the full year 2021. Operating expenses for the fourth quarter of 2022 increased primarily due to a $4.2 million onetime noncash impairment charge related to long-lived assets recorded during the fourth quarter of 2022 as well as to additional headcount, stock-based compensation expense and marketing costs. Operating expenses for the full year 2022 increased primarily due to onetime noncash charges, including a $16.6 million goodwill impairment charge recorded during the third quarter of 2022, a $4.2 million impairment charge related to the long-lived assets recorded during the fourth quarter of 2022. Adjusted EBITDA, a non-GAAP measure, was negative $8.1 million for the fourth quarter of 2022 compared to negative $3.4 million for the fourth quarter of 2021. Free cash flow, a non-GAAP measure, which we define as cash provided by or used in operating activities, less purchases of property, plant and equipment, was negative $12.8 million for the fourth quarter of 2022 compared to negative $10.5 million for the fourth quarter 2021."
}